Exiqon Licenses LNA Technology to Becton Dickinson | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exiqon today announced it has granted a non-exclusive license for its locked nucleic acids technology to Becton Dickinson for the development of diagnostics for infectious diseases.

Under the terms of the deal, Exiqon will receive upfront and milestone payments and royalties on global sales of products stemming from the agreement. No other financial terms were disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.